Nervous Disorder TRIZ Cases

MMP-14 inhibition helps predict mesenchymal stem cell potency, improving biomarker-based evaluation for Alzheimer's and HLHS treatment.

A norepinephrine reuptake inhibitor plus muscarinic antagonist boosts pharyngeal muscle activity to reduce apnea severity without CPAP discomfort.

User behavior monitoring detects deviations in inhalation patterns and prompts adjustments to keep aerosol ingredient delivery consistent.

APAP, ibuprofen, and antihistamines replace DM-based OTC cough formulas to relieve cold and flu symptoms with lower abuse risk and fewer side effects.

Digital immunoassay with anti-tau antibodies improves p-Tau 217 detection accuracy for earlier Alzheimer's diagnosis and treatment.

An EMF-responsive Lgr4 promoter improves in vivo gene on-off control with lower basal expression and stronger responsiveness than earlier promoters.

Novel mPTP inhibitor compounds use targeted structural substitutions to improve brain penetration and selectivity while preserving inhibition efficacy.

Uronic acid harmine salts improve solubility, support oral mucosal absorption, and reduce bioavailability variability across patients.

Bupropion inhibits dextromethorphan metabolism to sustain plasma levels, reduce adverse events, and support less frequent dosing.

Novel LRRK2 inhibitor compounds reduce Ser910 and Ser935 phosphorylation to block neuronal death pathways in Parkinson's disease.

Ketamine prodrugs improve oral bioavailability and sustain plasma exposure to reduce first-pass loss and high-Cmax side effects in CNS treatment.

A single OV329-based therapy targets refractory CDKL5 seizures to reduce symptoms and improve cognitive and functional outcomes.

Neurotransmitter transporter-binding conjugates deliver oligonucleotides across the BBB to specific neurons, improving CNS targeting and reducing side effects.

Nitroxide compounds such as Tempol restore tidal volume and minute ventilation in opioid-induced respiratory depression without reversing analgesia.

Drug-induced neuroplasticity is paired with eye-tracked oculomotor, visual, and vestibular tasks to improve rehabilitation feedback and recovery.

Hydroxy-substituted stiripentol derivatives improve metabolic stability while preserving strong lactate dehydrogenase inhibition for antiepileptic and anticancer use.

Tailored peptide sequences tune GLP-1 and glucagon receptor activity to drive weight loss and metabolic benefits with fewer side effects.

Plant-derived exosomes directly break down cellular protein aggregates, offering an ALS treatment path with fewer side effects and scalable production.

A motor-driven cam releases a spring-loaded piston in timed steps, enabling precise transdermal dosing with a smaller reusable-disposable format.

Using adenovirus-36 E4orf1 to improve glycemic control, this case reduces beta-amyloid plaques and helps preserve cognition in Alzheimer's disease.

Perillyl alcohol temporarily opens the blood-brain barrier, enabling intraarterial CAR-T and drug delivery to CNS tumors.

Glyceryl tribenzoate and dibenzoate slowly release sodium benzoate, extending exposure and reducing dosing frequency for neurodegenerative treatment.

Targeted ASPA expression lets neurons catabolize NAA into acetate for AcCoA and ATP synthesis, improving resistance to brain oxidative stress.

Low-dose mTOR inhibitor dosing can relieve Smith-Kingsmore syndrome symptoms while minimizing disruption to sleep and locomotor activity.

Specific pH control and stabilizing agents limit trans-metalation and radiolytic degradation, preserving radiochemical purity during storage.

Tertiary alcohol compounds selectively inhibit PI3Kγ kinase activity to improve therapeutic efficacy while limiting off-target effects.

Anti-CGRP antibodies target CGRP to reduce migraine frequency and depressive symptoms with one therapy for overlapping headache and psychiatric needs.

By binding excess NGF without fully depleting it, p75NTR-Fc fusion proteins relieve companion animal pain while lowering joint degeneration risk.

Controlled oral esketamine dosing balances MDD efficacy with lower mutagenicity risk over extended treatment.

Pamoic acid in polymer microspheres limits initial burst release below 15% while sustaining therapeutic drug levels for up to 6 months.

Targeting renal SLC6A19 transport offers a non-enzyme route to control phenylalanine in PKU and reduce neurological damage risk.

Blocking P2X4 receptors helps prevent mast cell activation and treat drug-triggered pseudo-allergic symptoms across multiple systems.

Nitrogen and halogen modified retinoids improve RAR activation potency and aqueous solubility while supporting neurite outgrowth and cell survival.

AAV vectors co-express a therapeutic payload and secreted anti-inflammatory protein to address genetic defects and microglial activation.

Selective Nav1.7-blocking peptides reduce nociceptor signaling and chronic pain while avoiding opioid addiction risk and off-target side effects.

A three-strain Lactobacillus blend helps counter aging-related grip strength loss and gut flora imbalance linked to sarcopenia and obesity.

Deuterium-enriched MDAI analogs improve ADME and metabolic stability while reducing toxicity risks in brain disorder treatment.

Cannabinoid acids such as CBDA and THCA target tau, amyloid beta, and calcium imbalance to improve long-term Alzheimer's treatment.

Ebselen derivatives target complex I deficiency and oxidative stress to improve respiratory chain function and slow mitochondrial illness progression.

A Bifidobacterium breve BBr16 strain improves aging-related cognitive disorder by modulating the gut-liver axis and lowering inflammation.

An AAV9 PLA2G6 cassette removes WPRE to lower oncogenic risk while preserving therapeutic expression for infantile neuroaxonal dystrophy.

Conditioned fibroblasts target cerebral palsy causes by reducing CNS inflammation and promoting angiogenesis and neurogenesis.

Liposome-encapsulated PAH mRNA restores phenylalanine metabolism, reducing PKU burden and rapidly lowering phenylalanine levels.

SOX9-driven direct reprogramming turns iPSCs into OPCs in 1-8 days with higher differentiation efficiency and reduced immune response risk.

Sequence-specific antisense oligonucleotides lower mutant huntingtin in the CNS while preserving wild-type expression to slow Huntington's disease progression.

Humanized and chimeric CD38 antibodies improve myeloma targeting with high-affinity binding, ADCC, CDC, and reduced immunogenicity.

A VHH antibody targets the SVQIVYKPV Tau epitope to inhibit aggregation, enter cells, and reduce neurofibrillary tangle formation.

Vitamin E TPGS masks atomoxetine bitterness in oral solutions, improving pediatric compliance with safer long-term use and 45-day shelf life.

Enantiomerically pure CNS compounds use tunable molecular substituents to improve treatment across depression, schizophrenia, and Alzheimer's aggression.

Plant-derived pistachio melatonin bound to arginine, tryptophan, lutein, and resveratrol improves bioavailability and sleep-related receptor activity.

A novel Bifidobacterium longum subspecies utilizes human milk oligosaccharides and plant-derived carbohydrates to support intestinal flora across age groups.

Bupropion metabolites inhibit CYP2D6 enzymes to extend dextromethorphan metabolic lifetime, resolving rapid clearance bottlenecks in extensive metabolizers.

Intranasal anti-CD3 antibodies modulate CNS inflammation by targeting microglia through the nasal-brain interface, bypassing systemic immune exposure.

Targeting Vps10p-domain receptors addresses underlying causes of mental disorders by modulating synaptic plasticity rather than merely alleviating symptoms.

Merging dimethylfumarate and teriflunomide into one tablet lowers required doses while maintaining efficacy against multiple sclerosis relapse rates.

Segments aspirin from alkaline calcium carbonate to prevent hydrolytic degradation while maintaining rapid dissolution rates.

Specific structural modifications on the pyridine ring enable selective binding to CB2 receptors while minimizing unwanted CB1 activity.

Polymerized non-fibrillogenic peptides present localized conformational epitopes to elicit specific immune responses against pathological protein aggregates.

Amino acid sequences bind multitarget scavenger receptors with high affinity to modulate disease pathways.

Spiro-cyclic amine derivatives bind selectively to the S1P5 receptor subtype, resolving cardiovascular side effects from non-selective S1P modulation.

Integrated assembloids replicate the corticospinal tract circuit to enable high-throughput therapeutic screening.

Anti-human ADRB3 monoclonal antibody regulates receptor activity to modulate immune responses.

A pharmaceutical composition combining specific THC and CBD ratios with defined terpene profiles to treat behavioral symptoms in autism spectrum disorder.

Lactobacillus composition restores intestinal flora balance to resolve antibiotic-induced anxiety by increasing beneficial compound synthesis.

Purified cannabidiol at 5-50 mg/kg/day reduces tonic seizure frequency by up to 55% in CLCN4 mutation patients.

Systemic vascular endothelial growth factor administration transiently expands blood-brain barrier permeability to facilitate therapeutic agent delivery.

EF1α promoter lentiviral vector boosts ABCD1 expression in stem cells, resolving low transfer efficiency and inadequate therapeutic effects.

N-alkylated peptide analogues target PDZ domains to block the NMDA receptor/PSD-95 interaction.

R(-)-ketamine composition removes psychotomimetic effects and cognitive impairment while maintaining rapid antidepressant efficacy.

A mobile inhaler system connects to multiple liquid containers for controlled substance delivery.

Light-responsive opsin proteins hyperpolarize cholinergic interneurons to disrupt reward-related behaviors.

A triazolotriazine derivative improves bioavailability and inhibits tumor growth.

Monoclonal antibodies inhibit alpha9 integrin function to treat cancer metastasis and inflammatory diseases.

Fully human monoclonal antibodies bind the RET receptor tyrosine kinase to inhibit tumor growth.

Adeno-associated virus vectors deliver antibody genes to brain endothelial cells, bypassing blood-brain barrier obstruction and reducing immunogenicity.

A pharmaceutical liquid composition uses glycerol and hydroxyethylcellulose to increase viscosity for precise syringe dosing.

Structural modifications reduce CYP3A4 time-dependent inhibition and hERG channel risks, improving oral exposure for treating fibrotic diseases.

Corin and Frizzled-5 marker purification isolates homogeneous midbrain dopaminergic progenitors, reducing tumor risks in Parkinson's disease therapies.

A conjugate recruits immune cells to clear protein aggregates.

Co-administering GAD, IL-10, and GDNF genes achieves synergistic pain relief at lower doses, reducing toxicity and side effects.

Prevotella histicola preparations reduce disease severity without side effects by promoting anti-inflammatory cytokines.

siRNA degrades QR2 mRNA to lower oxidative stress, addressing symptomatic treatment limits.

Arylsulfonamide compounds inhibit muscarinic acetylcholine receptor M5 activity through specific heterocyclic substitution patterns.

Sucrose and nonionic surfactant stabilize aqueous fusion proteins, minimizing particle formation and degradation during storage.